neostigmine methylsulfate · Fresenius Kabi Usa · NDA 203629
Neostigmine Methylsulfate
Earliest generic entry, as listed · earliest of 3 marketed strengths
Open now
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 3
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 203629 · 001 · RLD | solution, intravenous | 5MG/10ML (0.5MG/ML) | open |
| 203629 · 002 · RLD | solution, intravenous | 10MG/10ML (1MG/ML) | open |
| 203629 · 003 · RLD | solution, intravenous | 3MG/3ML (1MG/ML) | open |